A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Acorda seems to be wandering in a sine wave pattern as alternatively optimistic and pessimistic views of the commercial potential of their multiple sclerosis drug Ampyra. Ampyra is far from a proven winner but the share price will likely rebound with the next quarterly PR. In the meantime, Acorda has lowered their burn substantially and maintains a decent cash position.